Nelarabine Injection Now Available

Share Facebook icon Twitter icon Linkedin icon

Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Nelarabine Injection, 250 mg per 50 mL, in a single-dose vial.

Meitheal will offer Nelarabine Injection in a carton of 6 vials.


Nelarabine Injection is a nucleoside metabolic Inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens link.

Learn more about Nelarabine Injection.

This Website Uses Cookies

This website uses cookies to help us give you the best experience when you visit. By clicking “Accept Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can read more about our use of cookies in our Privacy Policy.

Accept cookies Reject cookies